Your browser is no longer supported. Please, upgrade your browser.
Protalix BioTherapeutics, Inc.
Index- P/E- EPS (ttm)-0.22 Insider Own27.50% Shs Outstand45.38M Perf Week17.87%
Market Cap281.37M Forward P/E6.89 EPS next Y0.90 Insider Trans0.00% Shs Float29.81M Perf Month21.81%
Income- PEG- EPS next Q-0.02 Inst Own10.64% Short Float5.34% Perf Quarter56.96%
Sales62.90M P/S4.47 EPS this Y104.50% Inst Trans- Short Ratio1.65 Perf Half Y66.67%
Book/sh-0.78 P/B- EPS next Y8900.00% ROA- Target Price- Perf Year79.71%
Cash/sh- P/C- EPS next 5Y25.00% ROE- 52W Range2.81 - 7.02 Perf YTD70.80%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-15.81% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low110.32% ATR0.33
Employees207 Current Ratio- Sales Q/Q9.80% Oper. Margin- RSI (14)63.53 Volatility7.62% 6.55%
OptionableYes Debt/Eq- EPS Q/Q36.40% Profit Margin- Rel Volume1.79 Prev Close6.20
ShortableYes LT Debt/Eq- EarningsMar 30 BMO Payout- Avg Volume964.91K Price5.91
Recom2.00 SMA2014.28% SMA5017.09% SMA20046.93% Volume1,253,127 Change-4.68%
Jun-08-20Reiterated H.C. Wainwright Buy $3 → $11
Apr-17-17Reiterated Rodman & Renshaw Buy $4 → $5
Apr-04-16Initiated Rodman & Renshaw Buy $3.50
Apr-23-15Upgrade Jefferies Hold → Buy $2 → $2.60
Nov-12-14Reiterated R. F. Lafferty Buy $8 → $5
Jan-24-14Initiated R. F. Lafferty Buy $8
May-02-12Reiterated Oppenheimer Outperform $9 → $11
May-02-12Downgrade Canaccord Genuity Buy → Hold $8 → $8
Apr-30-12Downgrade Auriga Buy → Hold $8 → $8
Oct-13-11Initiated Morgan Joseph Hold
Mar-17-11Downgrade WBB Securities Strong Buy → Buy $10
Nov-09-10Reiterated Oppenheimer Outperform $10 → $12
Oct-14-10Reiterated UBS Buy $9 → $10.75
Dec-02-09Reiterated Hapoalim Outperform $10 → $12
Sep-22-09Initiated Canaccord Adams Buy
Sep-02-09Initiated Hapoalim Outperform $10
Dec-01-08Reiterated Oppenheimer Outperform $6 → $4
Mar-11-08Initiated UBS Buy $6
Nov-20-07Initiated CIBC Wrld Mkts Sector Outperform $7
Apr-07-21 05:15AM  
Mar-30-21 06:50AM  
Mar-22-21 06:50AM  
Mar-04-21 06:50AM  
Feb-24-21 08:03AM  
Feb-23-21 08:04AM  
Feb-22-21 03:20AM  
Feb-18-21 08:02AM  
Feb-12-21 05:54AM  
Feb-11-21 09:16PM  
Feb-10-21 07:01AM  
Feb-01-21 06:50AM  
Jan-04-21 06:50AM  
Dec-30-20 06:50AM  
Dec-21-20 06:40AM  
Dec-15-20 07:15AM  
Nov-30-20 03:38PM  
Nov-27-20 06:50AM  
Nov-05-20 06:50AM  
Oct-29-20 01:33PM  
Oct-26-20 06:50AM  
Oct-22-20 06:50AM  
Oct-20-20 12:13PM  
Oct-02-20 08:00AM  
Sep-08-20 06:55AM  
Aug-24-20 06:50AM  
Aug-20-20 03:44PM  
Aug-11-20 06:50AM  
Aug-10-20 06:50AM  
Aug-06-20 01:02PM  
Aug-03-20 09:13AM  
Jul-23-20 02:29PM  
Jul-22-20 07:28PM  
Jun-18-20 12:20PM  
Jun-08-20 05:00PM  
Jun-03-20 08:46PM  
Jun-01-20 06:50AM  
May-29-20 09:43AM  
May-28-20 06:50AM  
May-22-20 04:05PM  
May-11-20 06:50AM  
Mar-18-20 12:12PM  
Mar-16-20 06:50AM  
Mar-12-20 08:04AM  
Mar-05-20 07:00AM  
Feb-11-20 10:52AM  
Feb-10-20 04:05PM  
Feb-06-20 06:50AM  
Feb-04-20 09:00AM  
Jan-30-20 07:30AM  
Jan-14-20 05:09PM  
Dec-19-19 06:50AM  
Dec-09-19 04:05PM  
Nov-29-19 10:37PM  
Nov-27-19 06:50AM  
Nov-19-19 09:26AM  
Nov-18-19 06:50AM  
Nov-13-19 11:59AM  
Nov-07-19 09:25AM  
Oct-31-19 10:34AM  
Oct-29-19 07:00AM  
Oct-17-19 07:40AM  
Sep-25-19 06:22PM  
Sep-24-19 07:00AM  
Sep-02-19 11:40AM  
Aug-30-19 04:15PM  
Aug-26-19 03:18PM  
Aug-22-19 08:45AM  
Aug-13-19 04:05PM  
Aug-08-19 07:30AM  
Aug-01-19 10:32AM  
Jul-29-19 04:01PM  
Jul-11-19 02:16PM  
Jun-18-19 10:27AM  
Jun-17-19 07:00AM  
Jun-06-19 07:00AM  
May-31-19 08:58AM  
May-21-19 07:00AM  
May-14-19 12:50AM  
May-09-19 01:41AM  
May-06-19 08:15AM  
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundacao Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.